cla Antibody

What is CLA and what are its primary functions in the immune system?

CLA (Cutaneous Lymphocyte-Associated Antigen) functions as a homing receptor that facilitates the selective migration of memory and effector T cells to the skin . This cell surface glycoprotein plays a crucial role in directing immune responses to cutaneous sites. CLA binds specifically to E-selectin and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1), mediating T lymphocyte infiltration and adhesion at sites of skin inflammation . While CLA expression is predominantly associated with skin-homing T cells, it can also be detected on certain peripheral T cells, NK cells, monocytes, neutrophils, and CD1a+ dendritic cells . Molecularly, CLA comprises sialofucosylated glycans and sialyl Lewis x (sLex) structures that are recognized by specific antibodies such as HECA-452 .

How do different types of CLA antibodies function in research settings?

Research settings utilize multiple types of CLA antibodies, each serving distinct functions:

• Anti-Cutaneous Lymphocyte Antigen antibodies: Used to identify and study skin-homing T cells through techniques like flow cytometry, western blotting, and immunohistochemistry . The HECA-452 monoclonal antibody is particularly valuable for these applications, recognizing sialofucosylated glycans and sialyl Lewis x (sLex) .

• Complement-dependent Lymphocytotoxic Antibodies (CLA): Found in systemic lupus erythematosus (SLE) patients, these autoantibodies are studied for their effects on T cell responses, particularly their ability to modify alloreactive T cell subsets in the presence of complement .

• Antibody-conjugated CLA nanomicelles: Representing an innovative therapeutic approach, these complex structures utilize conjugated linoleic acid (CLA) incorporated into nanomicelles and coupled with specific antibodies to target parasites like Schistosoma mansoni .

Each type requires specific methodological approaches for isolation, characterization, and functional analysis in experimental settings.

How is CLA expression regulated on different T cell subsets?

CLA induction occurs differentially between T cell subtypes. It is readily induced on freshly generated Th1 and Tc1 cells but not typically on type 2 T cells under standard conditions . Anti-CD3 stimulation can induce CLA expression on Th2 cells, but only in serum-free medium . This indicates that serum components, particularly IL-4, play an inhibitory role in CLA expression.

Several factors modulate CLA expression:

• IL-4 inhibits both CLA expression and related α-fucosyltransferase mRNA expression

• IL-12 and/or staphylococcal enterotoxin B (SEB) can upregulate CLA expression on both Th2 and Tc2 cells

• IL-12 stimulation enables CLA expression on diverse T cell types, including bee venom phospholipase A2-specific Th1, Th2, Th0, and T regulatory 1 clones

Importantly, CLA expression appears dynamic rather than fixed, as it can be re-induced on T cells that had previously lost expression upon resting . This suggests skin-selective homing is not permanently restricted to specific functional or phenotypic T cell subsets.

What methodologies are used to detect and quantify CLA expression on immune cells?

Researchers employ several complementary techniques to detect and quantify CLA expression:

• Flow Cytometric Analysis: The primary method for quantifying CLA expression on various cell populations. The HECA-452 monoclonal antibody is typically used at concentrations ≤0.125 μg/test . This technique enables both identification of CLA+ cells and assessment of expression levels across different immune cell subsets.

• Western Blotting: Used to analyze CLA at the protein level, particularly useful for examining structural variants and post-translational modifications .

• Immunohistochemistry: Applied to formalin-fixed paraffin-embedded tissue sections to visualize CLA distribution in tissue contexts. The HECA-452 antibody performs optimally with low pH antigen retrieval, though high pH retrieval can also be used at concentrations ≤10 μg/mL . This approach provides spatial information about CLA distribution that flow cytometry cannot capture.

• Functional Assays: Beyond quantification, these assess the functional consequences of CLA expression, including cell migration, adhesion, and activation in response to appropriate stimuli .

For optimal results, researchers should carefully titrate antibodies for each application and include appropriate controls to distinguish specific from non-specific binding. Validation across multiple detection techniques strengthens confidence in expression data.

How do Complement-dependent Lymphocytotoxic Antibodies (CLA) affect T cell responses in autoimmune conditions?

Complement-dependent lymphocytotoxic autoantibodies (CLA) play a significant role in modulating T cell responses in autoimmune conditions, particularly systemic lupus erythematosus (SLE). These antibodies are invariably present in sera of patients with active SLE .

Research has demonstrated that CLA affects T cell responses through complement-dependent mechanisms. When CLA interacts with lymphocytes in the presence of complement, it can significantly alter both proliferative and cytotoxic T cell responses . This effect is entirely dependent on complement—when complement is absent, the antibodies show no effect on T cell function .

The impact of CLA on T cells appears to be subset-specific and depends on the cellular differentiation state:

• Pre-treatment of unsensitized precursor cells with CLA plus complement reduces and delays both proliferative and cytotoxic reactivity

• Pre-treatment of memory T cells with CLA plus complement selectively reduces cellular cytotoxicity without affecting proliferation

These findings suggest that CLA can modify the balance between different subsets of alloreactive T cells through complement-dependent mechanisms . This selective modulation may contribute to the dysregulated immune responses characteristic of SLE and potentially other autoimmune conditions. Understanding these mechanisms has important implications for developing targeted immunotherapies for autoimmune diseases.

What are the challenges in conjugating antibodies to nanomicelles for targeted therapy?

Conjugating antibodies to nanomicelles presents several methodological challenges that researchers must address to develop effective targeted therapies. Based on the research with CLA-W nanomicelles, key considerations include:

• Conjugation Chemistry: Selecting appropriate linker molecules is critical. In the case of antibody-CLA-W conjugates, researchers used succinic anhydride as a linker to create antibody-succinate (Ab-Su) intermediates . The chemistry must maintain antibody functionality while achieving stable conjugation.

• Activation and Coupling: The process requires precise control of activation conditions. For example, EDC.HCl/K-Oxyma was used to form an Oxyma active ester intermediate that could covalently couple with the primary amines of whey-CLA nanomicelles . Optimization of reactant ratios and reaction conditions is essential.

• Purification: Removing unconjugated antibodies and reagents requires appropriate purification techniques. Dialysis against graduated solvent systems (e.g., 40% DMF followed by 100% distilled water) is commonly used .

• Conjugation Efficiency Assessment: Quantitative assays are needed to determine conjugation efficiency. Indirect ELISA is effective for quantifying unconjugated antibodies in the supernatant after centrifugation, allowing calculation of the percentage of antibodies conjugated to nanomicelles . High-efficiency conjugation (>99%) is achievable with optimized protocols .

• Stability Validation: Ensuring the stability of antibody-conjugated nanomicelles is crucial. In vitro serum stability tests and storage stability assessments are necessary. Parameters like particle size, polydispersity index (PDI), and zeta potential should remain consistent after serum exposure and during storage .

• Biocompatibility: Hemolytic assays and other biocompatibility tests are essential to ensure the safety of the conjugated nanomicelles for in vivo applications .

Successfully addressing these challenges enables the development of stable, effective antibody-conjugated nanomicelles with potential applications in targeted therapies.

How are antibody-conjugated CLA nanomicelles developed for targeted parasitic therapy?

The development of antibody-conjugated CLA nanomicelles represents an innovative approach for targeted parasitic therapy, particularly against Schistosoma mansoni. This methodology involves several sophisticated steps:

• Design and Synthesis of the Carrier System: Researchers created an amphiphilic CLA-loaded whey protein co-polymer (CLA-W) as an intravenous injectable protein nanocarrier . This base system provides structural stability and appropriate pharmacokinetic properties.

• Antibody Selection and Purification: Specific antibodies targeting relevant parasite antigens are purified from immune sera. Two types were used in this research: rabbit anti-Schistosoma mansoni infection (anti-SmI) and anti-Schistosoma mansoni alkaline phosphatase specific IgG antibodies .

• Conjugation Chemistry: The antibodies are conjugated to the surface of CLA-W co-polymer using succinic anhydride as a linker . This process involves:

  • Creating antibody-succinate (Ab-Su) by reacting purified antibodies with succinic anhydride

  • Activating the antibody-succinate with EDC.HCl/K-Oxyma

  • Covalently coupling the activated complex with the primary amines of whey-CLA nanomicelles

• Purification and Characterization: The antibody-CLA-W conjugates undergo dialysis against graduated solvent systems and lyophilization . The resulting nanomicelles are characterized for:

  • Particle size and polydispersity index

  • Zeta potential

  • Conjugation efficiency (typically >99%)

  • In vitro serum stability

  • Storage stability

• Functional Validation: The schistosomicidal effects are evaluated in animal models against both early (schistosomula) and late (adult worm) stages of infection .

This approach has demonstrated significant efficacy, with anti-SmI-coupled CLA-W producing the highest effects against both early and late stage parasites, resulting in substantial reductions in worm and egg burdens (64.6%-89.9% reductions in worm number; 72.5–94% and 66.4–85.2% reductions in hepatic eggs and granulomas, respectively) .

What mechanisms underlie the enhanced efficacy of antibody-conjugated CLA nanomicelles against parasitic infections?

The remarkable efficacy of antibody-conjugated CLA nanomicelles against parasitic infections, particularly schistosomiasis, stems from several synergistic mechanisms:

• Dual-Action Approach: The system combines the direct schistosomicidal effects of CLA with targeted antibody delivery . CLA (conjugated linoleic acid) activates the schistosome tegument-associated sphingomyelinase, leading to disruption of the outer membrane .

• Enhanced Target Recognition: The conjugated antibodies (anti-SmI or anti-SmAP) provide specific recognition of parasite surface antigens, enabling precise targeting of the therapeutic payload .

• Membrane Disruption Cascade: When CLA disrupts the parasite's outer membrane, it allows host antibodies to access previously concealed apical membrane antigens . This was confirmed by electron microscopy, which revealed "severe injury and evidence of cell death" in the adult worm tegument .

• Increased Antigen Exposure: Treatment with antibody-CLA-W nanomicelles increases the exposure of antigens on the worm surface, as demonstrated by enhanced immunofluorescence staining . This creates a positive feedback loop, potentially allowing more host antibodies to bind and further damage the parasite.

• Immune-Mediated Enhancement: The observations confirm an "immune-mediated enhanced effect of the schistosomicidal action of CLA" . This suggests the nanomicelles not only deliver the therapeutic agent but also stimulate the host's immune response against the parasite.

• Size-Optimized Delivery: The nano-sized delivery system likely enhances bioavailability and penetration into parasite tissues, improving therapeutic efficacy .

These mechanisms collectively contribute to the system's efficacy, reducing worm numbers by up to 89.9% and hepatic eggs by up to 94% . The approach demonstrates the potential of nanotechnology-based immunotherapy not only for schistosomiasis but potentially for other parasitic infections where chemotherapy has shown immune dependence .

How might future research extend the applications of CLA antibody technologies?

Future research on CLA antibody technologies shows promise in multiple directions, building on current findings and extending to new applications:

• Expanded Parasite Targeting: The success of antibody-conjugated CLA nanomicelles against Schistosoma mansoni suggests potential applications against other parasitic infections where chemotherapy has shown immune dependence . Adapting this approach to target other helminth infections, protozoan parasites, or even fungal pathogens represents a logical extension.

• Vaccine Development: The identification of immunodominant antigens like Schistosoma mansoni fructose biphosphate aldolase (SmFBPA) through anti-SmI serum reactivity opens new avenues for vaccine development . These antigens merit "serious attention as a therapeutic and vaccine candidate" .

• Personalized Immunotherapy: Refinement of antibody selection and nanomicelle composition could enable more personalized approaches to treatment, potentially addressing drug resistance issues in parasitic diseases.

• Skin Immunotherapy: Given CLA's role in skin-homing of T cells , developing targeted therapies for skin conditions represents another promising direction. CLA expression on different T cell subsets (Th1, Th2, etc.) could be exploited to deliver subset-specific therapies for conditions like atopic dermatitis or psoriasis.

• Autoimmune Disease Applications: Understanding the mechanisms by which complement-dependent lymphocytotoxic antibodies (CLA) modify T cell responses could inform new therapeutic approaches for autoimmune conditions like SLE.

• Advanced Diagnostic Tools: The specificity of CLA antibodies like HECA-452 for skin-homing T cells could be leveraged to develop diagnostic tools for skin conditions characterized by abnormal T cell infiltration.

• Combination Therapies: Integrating antibody-conjugated nanomicelles with conventional treatments might enhance efficacy while reducing dosage requirements and side effects.

These future directions highlight the versatility of CLA antibody technologies and their potential to transform approaches to both parasitic diseases and immunological disorders.

What quality control measures are essential when working with CLA antibodies?

Rigorous quality control is crucial when working with CLA antibodies to ensure research reproducibility and validity. Based on established methodologies, essential quality control measures include:

• Purity Assessment: Verify antibody purity using SDS-PAGE, with acceptable standards typically greater than 90% . This ensures minimal contamination with other proteins that could interfere with experimental results.

• Aggregation Analysis: Determine antibody aggregation levels using HPLC, with less than 10% aggregation considered acceptable . Aggregated antibodies can cause non-specific binding and precipitation issues.

• Sterility Verification: Confirm proper filtration (e.g., 0.2 μm post-manufacturing filtration) to ensure sterility, particularly important for in vivo applications and cell culture experiments.

• Binding Specificity Validation: Conduct cross-reactivity tests to confirm the antibody binds specifically to the target antigen (e.g., sialofucosylated glycans and sialyl Lewis x for HECA-452) .

• Functional Verification: For antibody-conjugated nanomicelles, validate conjugation efficiency using quantitative indirect ELISA, with optimal conjugation rates approaching 99% .

• Stability Testing: Assess stability under various conditions, including:

  • Serum stability (e.g., incubation with 10% FBS for six hours)

  • Storage stability (e.g., at -20°C for extended periods)

  • Monitor parameters such as particle size, PDI, and zeta potential before and after stability challenges

• Biocompatibility Assessment: For therapeutic applications, conduct hemocompatibility and hemolytic assays to ensure safety .

• Titration for Optimal Performance: Carefully titrate antibodies for each specific application (e.g., ≤0.125 μg/test for flow cytometry; ≤10 μg/mL for immunohistochemistry) .

Implementing these quality control measures helps ensure consistent, reliable results when working with various CLA antibodies and their conjugates.

How should researchers interpret contradictory data regarding CLA function across different experimental models?

Interpreting contradictory data regarding CLA function across different experimental models requires a systematic approach considering multiple factors:

• Context-Dependent Expression: Recognize that CLA expression and function may be fundamentally context-dependent. For instance, while CLA was initially reported to be predominantly expressed on Th1 cells, subsequent research demonstrated its expression could be induced on Th2 cells under specific conditions (absence of serum or IL-4) . This suggests environmental factors strongly influence CLA biology.

• Methodological Differences: Carefully evaluate methodological variations between studies:

  • Culture conditions (serum vs. serum-free)

  • Stimulation protocols (anti-CD3, IL-12, SEB)

  • Cell isolation techniques

  • Detection methods and antibody clones used

• Dynamic Regulation: Consider the dynamic nature of CLA expression. Studies show CLA can be re-induced on T cells that had previously lost expression upon resting , indicating its expression is not static but regulated by ongoing cellular processes.

• Different CLA Types: Distinguish between different types of CLA being studied:

  • Cutaneous Lymphocyte-Associated Antigen on T cells

  • Complement-dependent Lymphocytotoxic Antibodies in SLE

  • Conjugated Linoleic Acid in nanomicelle applications

• Species Differences: Account for potential species-specific variations in CLA expression and function between human and animal models.

• Functional vs. Phenotypic Analysis: Integrate both phenotypic (expression) and functional (migration, adhesion) data. As noted in research, "skin-selective homing is not restricted to functional and phenotypic T cell subsets" , highlighting the importance of functional validation.

• Reconciliation Strategies:

  • Design experiments that directly address contradictions

  • Use multiple complementary techniques to verify findings

  • Consider temporal dynamics of CLA expression and function

  • Clearly define the specific aspect of CLA being studied

By systematically addressing these factors, researchers can better interpret seemingly contradictory data and develop more nuanced models of CLA function across different experimental contexts.

What technical considerations are critical for successful antibody conjugation to nanomicelles?

Successful antibody conjugation to nanomicelles requires careful attention to several technical considerations that can significantly impact the quality and functionality of the final product:

• Antibody Preparation: Start with high-purity antibodies (>90% as determined by SDS-PAGE) . Antibody quality directly influences conjugation efficiency and specificity of the final construct.

• Conjugation Chemistry Selection: Choose appropriate chemistry based on available functional groups. For anti-SmI/anti-SmAP IgG antibodies, successful conjugation to CLA-W nanomicelles utilized succinic anhydride as a linker :

  • The process begins with formation of antibody-succinate (Ab-Su) by adding succinic anhydride to purified antibodies

  • Activation with EDC.HCl/K-Oxyma creates an Oxyma active ester intermediate

  • This intermediate covalently couples with primary amines on whey-CLA nanomicelles

• Reaction Conditions Optimization:

  • Solvent selection: DMF with triethylamine worked effectively for the initial antibody-succinate formation

  • Reaction time and temperature: 24 hours at 25°C for both antibody succinylation and coupling reactions

  • Reagent ratios: Precise amounts of activating agents (e.g., 0.2 mmol EDC.HCl/K-Oxyma) are critical

• Purification Protocol: Implement effective purification methods to remove unreacted components:

  • Dialysis against graduated solvent systems (e.g., 40% DMF followed by 100% distilled water)

  • Lyophilization to obtain stable, dry product for storage

• Conjugation Validation: Quantify conjugation efficiency using appropriate analytical methods:

  • Quantitative indirect ELISA comparing antibody concentration before and after conjugation

  • Achievement of >99% conjugation efficiency is possible with optimized conditions

• Physicochemical Characterization: Assess key parameters before and after conjugation:

  • Particle size and polydispersity index (PDI)

  • Zeta potential

  • Morphological characteristics

• Stability Assessment: Verify stability under relevant conditions:

  • Serum stability (e.g., incubation with 10% FBS)

  • Long-term storage stability (e.g., -20°C for four months)

• Functional Verification: Confirm that conjugated antibodies retain their ability to bind target antigens using appropriate binding assays .

Attention to these technical considerations ensures the production of stable, functional antibody-conjugated nanomicelles suitable for targeted therapeutic applications.